Dr. Keith Flaherty Discusses Long-Term Data from the COLUMBUS Trial

Keith T. Flaherty, MD
Published: Wednesday, Nov 09, 2016



Keith T. Flaherty, MD, director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and professor of Medicine, Harvard Medical School, discusses the results from the COLUMBUS trial, testing encorafenib plus binimetinib compared to vemurafenib or encorafenib as single agents.

While the phase III data that was observed at just under 15 months, showed that the combination provided superior progression-free survival (PFS), long term data is still yet to be seen. However, Flaherty mentioned that there is some promising durability shown in the patients enrolled in the stage I/II COLUMBUS trials.


Keith T. Flaherty, MD, director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and professor of Medicine, Harvard Medical School, discusses the results from the COLUMBUS trial, testing encorafenib plus binimetinib compared to vemurafenib or encorafenib as single agents.

While the phase III data that was observed at just under 15 months, showed that the combination provided superior progression-free survival (PFS), long term data is still yet to be seen. However, Flaherty mentioned that there is some promising durability shown in the patients enrolled in the stage I/II COLUMBUS trials.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x